Zevra Therapeutics (ZVRA) Cash from Operations (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Cash from Operations came in at 6142000.0 in Q1 2026, up 174.7% YoY from 2235877.27 in Q1 2025, and up 11.35% on a QoQ basis from 5516000.0 in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Cash from Operations (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Cash from Operations data on file, last reported at 6142000.0 in Q1 2026.
- Quarterly Cash from Operations rose 174.7% year-over-year to 6142000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12766000.0 (up 120.68% YoY) and the FY2025 annual result came in at 1598000.0, up 97.71% from the prior year.
- Cash from Operations climbed to 6142000.0 in Q1 2026, from 5516000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6142000.0 in Q1 2026 to a low of 19109000.0 in Q2 2024.
- A 5-year average of 6904294.12 and a median of 4628000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 426.18% — and 2026, when it soared 174.7%.
- Tracing ZVRA's Cash from Operations over 5 years: stood at 4462000.0 in 2022, then tumbled by 262.12% to 16158000.0 in 2023, then dropped by 0.57% to 16250000.0 in 2024, then soared by 133.94% to 5516000.0 in 2025, then climbed by 11.35% to 6142000.0 in 2026.
- The last three Cash from Operations figures came in at 6142000.0 (Q1 2026), 5516000.0 (Q4 2025), and 4709000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 17.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.03 Mn |
| Mar 31, 2026 | 6.14 Mn |
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Mar 31, 2025 | -8.22 Mn |
| Dec 31, 2024 | -16.25 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -19.11 Mn |
| Mar 31, 2024 | -16.17 Mn |
| Dec 31, 2023 | -16.16 Mn |
| Sep 30, 2023 | -4.63 Mn |
| Jun 30, 2023 | -8.70 Mn |
| Mar 31, 2023 | -4.05 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -6.60 Mn |
| Jun 30, 2022 | -4.10 Mn |
| Mar 31, 2022 | -3.55 Mn |
| Dec 31, 2021 | -848,000.00 |
| Sep 30, 2021 | -2.73 Mn |